11/5/2026

speaker
Mark
Conference Operator

Good morning, ladies and gentlemen, and welcome to Cognition Therapeutics, Inc.'s third quarter 2026 earnings conference call. My name is Mark, and I will be your conference operator today. This call is being recorded. I would like to turn the presentation over to your host for today's call, Mike Moyer, Managing Director for Labsite Advisors. Please proceed, Mr. Moyer.

speaker
Mike Moyer
Managing Director, Labsite Advisors

Thank you, operator, and good morning, everyone. Welcome to Cognition Therapeutics' third quarter 2026 conference call. With me today are Lisa Ricciardi, President and Chief Executive Officer, John Doyle, Chief Financial Officer, and Dr. Tony Caggiano, Chief Medical Officer. This morning, the company issued a press release detailing its financial results for the quarter. We encourage everyone to read this morning's press release as well as Cognition's Form 10-Q, which is now filed with the SEC and available on our website. In addition, this conference call is being webcast through the company's website and will be archived for 30 days. Please note that certain information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to the risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in Cognition's press releases and SEC filings. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast. Cognition undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. With that, I would now like to turn the call over to Lisa Ricciardi.

speaker
Lisa Ricciardi
President and Chief Executive Officer

Lisa Ricciardi Mike, thank you, and good morning, everyone. As you can see on the agenda, first topic we'd like to cover on this call is the registrational plan for Zervimicine or CT1812 and the treatment of people with dementia with Lewy bodies, which we'll refer to in this call as DLB. Two weeks ago, we announced that we reached alignment with the FDA on a planned registrational trial for Zervimicine in people living with DLB. Investors who have been following Cognition are aware that this topic has been the subject of several meetings with the FDA. We conducted meetings in January, May, and October, and all along, we've encountered FDA staff at every step who are engaged and constructive. And as a result of our interactions, Cognition Therapeutics is the first company to align on a phase three trial with the FDA for this class of drugs to treat DLB, to treat the condition of DLB. Other companies have designed phase three trials for symptomatic treatment, such as antipsychotics or medications for agitation in this population. Dervimicine is unique in that it is designed to slow the course of the disease, not just treat the symptoms. I am proud that we have tackled an unchartered development path together with the FDA. Now, we're working to complete a protocol for Zervimicine's Phase III program. A complicating factor with DLV is a lack of biomarkers available to measure the progression of disease. Because of this, we and the FDA agreed on clinical endpoints that are aimed at showing changes in disease progressions. Now with that, let me introduce our Chief Medical Officer, Tony Caggiano, who can discuss these endpoints and the details of our trial. Tony?

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API